Here are the reasons for top movers today

AInvestThursday, Jan 25, 2024 5:58 pm ET

1min read

Vera Therapeutics' stock price increased on 2024-01-25 as the company presented positive 72-week data from its Phase 2b ORIGIN clinical trial, which showed eGFR stabilization in patients with IgA nephropathy. This was seen as an encouraging development.

$PCSA(PCSA)$SWVL(SWVL)$RDHL(RDHL)$CGON(CGON)

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.